Log In
BCIQ
Print this Print this
 

Rixubis (BAX 326)

  Manage Alerts
Collapse Summary General Information
Company Baxalta Inc.
DescriptionRecombinant Factor IX (rFIX) protein
Molecular Target Factor IX
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentMarketed
Standard IndicationHemophilia
Indication DetailsTreat and prevent bleeding in patients over 12 years old with hemophilia B; Treat and prevent bleeding in patients over 16 years old with hemophilia B; Treatment and prophylaxis of bleeding in hemophilia B patients; Treatment and prophylaxis of bleeding in hemophilia B pediatric patients
Regulatory Designation U.S. - Orphan Drug (Treat and prevent bleeding in patients over 12 years old with hemophilia B);
EU - Standard Review (Treatment and prophylaxis of bleeding in hemophilia B patients)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$32,000.0M

$12,639.9M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/11/2016

$32,000.0M

$12,639.9M

0

Get a free BioCentury trial today